180 related articles for article (PubMed ID: 37422593)
1. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML).
Gurney M; Mangaonkar AA; Lasho T; Finke C; Al-Kali A; Gangat N; Shah MV; Alkhateeb HB; Tefferi A; Sallman D; Xie Z; Viswanatha D; Reichard K; Al Ali N; Komrokji R; Padron E; Patnaik MM
Leukemia; 2023 Aug; 37(8):1753-1756. PubMed ID: 37422593
[No Abstract] [Full Text] [Related]
2. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis.
Saiki R; Momozawa Y; Nannya Y; Nakagawa MM; Ochi Y; Yoshizato T; Terao C; Kuroda Y; Shiraishi Y; Chiba K; Tanaka H; Niida A; Imoto S; Matsuda K; Morisaki T; Murakami Y; Kamatani Y; Matsuda S; Kubo M; Miyano S; Makishima H; Ogawa S
Nat Med; 2021 Jul; 27(7):1239-1249. PubMed ID: 34239136
[TBL] [Abstract][Full Text] [Related]
3. Characterization of chronic myelomonocytic leukemia with TP53 mutations.
Wang W; Routbort MJ; Loghavi S; Tang Z; Medeiros LJ; Wang SA
Leuk Res; 2018 Jul; 70():97-99. PubMed ID: 29908419
[No Abstract] [Full Text] [Related]
4. TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
Gurney M; Greipp PT; Gliem T; Knudson R; Al-Kali A; Gangat N; Lasho T; Mangaonkar AA; Finke CM; Patnaik MM
Leuk Res; 2023 Nov; 134():107391. PubMed ID: 37769597
[No Abstract] [Full Text] [Related]
5. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
[TBL] [Abstract][Full Text] [Related]
6. TP53 somatic mutations are associated with somatic mitogenome substitutions but not indels in colorectal cancer cells.
Skonieczna K; Jawień A; Marszałek A; Grzybowski T
J Gene Med; 2019 Jan; 21(1):e3063. PubMed ID: 30548163
[TBL] [Abstract][Full Text] [Related]
7. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.
Palomo L; Xicoy B; Garcia O; Mallo M; Ademà V; Cabezón M; Arnan M; Pomares H; José Larrayoz M; José Calasanz M; Maciejewski JP; Huang D; Shih LY; Ogawa S; Cervera J; Such E; Coll R; Grau J; Solé F; Zamora L
Am J Hematol; 2016 Feb; 91(2):185-92. PubMed ID: 26509444
[TBL] [Abstract][Full Text] [Related]
8. Age-related mutations and chronic myelomonocytic leukemia.
Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
[TBL] [Abstract][Full Text] [Related]
9. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
10. p53 Protein expression in chronic myelomonocytic leukemia-1 correlates with progression to leukemia and a poor prognosis.
Hattori N; Fukuchi K; Nakamaki T; Homma M; Ariizumi H; Nakashima H; Maeda T; Saito B; Yamochi-Onizuka T; Yanagisawa K; Matsuda I; Ota H; Tomoyasu S
Acta Haematol; 2011; 125(4):242-6. PubMed ID: 21335959
[No Abstract] [Full Text] [Related]
11. Whole genome sequencing identified new somatic mutations for chronic myelomonocytic leukemia.
Ying Y; Xie JJ; Wang HP; Mao P; Zhou W; Yang Z; Chen XY
Eur Rev Med Pharmacol Sci; 2016; 20(2):278-84. PubMed ID: 26875896
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.
Lee PJ; Yoo NS; Hagemann IS; Pfeifer JD; Cottrell CE; Abel HJ; Duncavage EJ
Exp Mol Pathol; 2017 Feb; 102(1):156-161. PubMed ID: 28093192
[TBL] [Abstract][Full Text] [Related]
13. CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
Watanabe J; Sato K; Osawa Y; Horiuchi T; Kato S; Hikota-Saga R; Maekawa T; Yamamura T; Kobayashi A; Kobayashi S; Kimura F
Int J Hematol; 2018 Jul; 108(1):47-57. PubMed ID: 29600428
[TBL] [Abstract][Full Text] [Related]
14. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.
Loghavi S; Curry JL; Garcia-Manero G; Patel KP; Xu J; Khoury JD; Torres-Cabala CA; Nagarajan P; Aung PP; Gibson BR; Goodwin BP; Kelly BC; Korivi BR; Medeiros LJ; Prieto VG; Kantarjian HM; Bueso-Ramos CE; Tetzlaff MT
J Cutan Pathol; 2017 Dec; 44(12):1075-1079. PubMed ID: 28885734
[TBL] [Abstract][Full Text] [Related]
15. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
[TBL] [Abstract][Full Text] [Related]
16. Genetic complexity of chronic myelomonocytic leukemia.
Patel AB; Deininger MW
Leuk Lymphoma; 2021 May; 62(5):1031-1045. PubMed ID: 33337259
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.
Link DC; Schuettpelz LG; Shen D; Wang J; Walter MJ; Kulkarni S; Payton JE; Ivanovich J; Goodfellow PJ; Le Beau M; Koboldt DC; Dooling DJ; Fulton RS; Bender RH; Fulton LL; Delehaunty KD; Fronick CC; Appelbaum EL; Schmidt H; Abbott R; O'Laughlin M; Chen K; McLellan MD; Varghese N; Nagarajan R; Heath S; Graubert TA; Ding L; Ley TJ; Zambetti GP; Wilson RK; Mardis ER
JAMA; 2011 Apr; 305(15):1568-76. PubMed ID: 21505135
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelomonocytic leukemia: myeloproliferative variant.
Onida F; Beran M
Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
20. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
Edelmann J; Tausch E; Landau DA; Robrecht S; Bahlo J; Fischer K; Fink AM; Bloehdorn J; Holzmann K; Böttcher S; Werner L; Kneba M; Gribben JG; Neuberg DS; Wu CJ; Hallek M; Döhner H; Stilgenbauer S
Leukemia; 2017 Mar; 31(3):734-738. PubMed ID: 27909343
[No Abstract] [Full Text] [Related]
[Next] [New Search]
